Stanford Gastrointestinal (GI) Cancer Program

Stanford Comprehensive Cancer Center
Palo Alto, California
Contact information:
- See website
- Phone: 650-498-6000
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Home » Find a NET Specialist » Stanford Gastrointestinal (GI) Cancer Program
Palo Alto, California
Doctors at Stanford Cancer Center actively research advanced imaging technologies that improve the diagnosis of neuroendocrine tumors and help track the effectiveness of treatment. Stanford NET specialists invented cutting-edge diagnostic methods and are leaders in researching new treatments for neuroendocrine tumors. Stanford offers multidisciplinary treatment for neuroendocrine tumors in the gastrointestinal tract, lungs, and adrenal glands.
Neurorendocrine Tumor Reseach Foundation collaborates w ith Stanford on a regular basis to offer patient and caregiver conferences in the San Francisco Bay Area. You can view videos of a recent conference and see members of the treatment team present.
NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.
George Fisher, MD, PhD, Stanford Cancer Center, is a leading authority on neuroendocrine tumors and